Aptamer Group February 2019
14th February 2019
- Aptamers for therapeutic drug monitoring in plasma
- Aptamer Group speaking at a premier aptamer conference
- Interesting applications in portable quantitative aptasensors and protease inhibitors
With lots of new data ongoing for multiple applications in the commercial and academic space, Aptamer Group would like to share with you information that may be of interest for your research and business goals.
The goal of this succinct but informative email is to keep you updated on aptamer research both at Aptamer Group and in general in applications such as bio and cell based assay development, biosensors, flow cytometry, bioprocess and other in vivo applications.
As always, we would love to hear from you to discuss how aptamers can be utilised as the preferred affinity/binding molecules in your research, diagnostics, drug discovery and drug development programs.
Our Novel Solutions – Therapeutic Drug Monitoring in Plasma
Specificity to Irinotecan and SN-38
- Developed with a commercial partner for biosensor based monitoring of drug and active metabolite
- Evaluated in plasma at therapeutically relevant levels
- Confirmed by Biolayer Interferometry (BLI) and ELISA- like assays.
Aptamer Group Gold Sponsor and Presenting at 6th Annual International Meeting
Aptamer Group is pleased to once again support and present our research at Aptamers 2019 to be held April 3-4, 2019 at St Hilda’s College Oxford, UK. Presented by The International Society on Aptamers (INSOAP) the goal of the symposium is to explore therapeutic, diagnostic, analytical and basic research applications and progress of aptamers by industry leaders and researchers alike.
Head of Research and Development Dr Christine Reinemann will be presenting Flexible monitoring of small molecules with Aptamer affinity reagents.
We look forward to supporting the aptamer community, sharing our aptamer knowledge, and networking with our colleagues at this premier event.
In Review and News
Singh, N. et.al. describe quantitative detection using aptamers that avoid antibody instability issues and amenable for integration into a portable device that complies well with the ASSURED (Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment free and Deliverable to end-users) mandate of WHO.
Malicki, S. et. al. describe development and characterisation of nanomolar aptamers that inhibit bovine trypsin with no cross reactivity to multiple related enzymes.
Watch for our announcements on new collaborations with strategic partners and our new catalogue aptamer data sheets.
If you would like information on any of the topics we have covered or anything else, please do not hesitate to get in touch.